On June 15, 2011, due to a flare of inflammatory back pain associated with a high CRP level, he was started on his first TNF inhibitor, golimumab, 50 mg/month subcutaneously. At that time, he did not report any symptoms suggestive of IBD, such as frequent diarrhea with urgency, mucus in the stool, abdominal cramping, or melena. One week after the first golimumab injection, his musculoskeletal symptoms improved significantly, allowing him to discontinue celecoxib. The gene discussed is TNF; the disease is inflammatory bowel disease.